• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 13, 2017

View Archived Issues

In the clinic

Vidac Pharma Ltd., of Jerusalem, reported data from a phase IIa trial testing VDA-1102 in patients with actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma. Read More

Other news to note

American Gene Technologies International Inc., of Rockville, Md., presented its approach for developing a functional cure for HIV infection at the Cell & Gene Meeting on the Mesa in La Jolla, Calif. Read More

Financings

Immunogen Inc., of Waltham, Mass., closed its public offering of about 16.7 million shares, including 2.2 million shares sold to cover the underwriters’ full overallotment option, priced at $6.50 per share. Read More

YL Biologics bringing CJ Healthcare’s biosimilar darbepoetin alfa to Japan

HONG KONG – YL Biologics Ltd. has inked a licensing deal to distribute a biosimilar for the treatment of anemia by Korea’s CJ Healthcare Ltd. in Japan. The drug, CJ-40001, is CJ Healthcare’s version of Amgen Inc.’s Aranesp (darbepoetin alfa). Read More

Virionhealth ‘DIps’ into Abingworth’s pockets with $17M series A round

DUBLIN – Virionhealth Ltd., a newly funded U.K. startup, raised up to £13 million (US$17 million) in series A funding to take forward a novel approach for preventing and treating respiratory viral infections, which relies on a long-recognized quirk of viral replication that has long been overlooked by the biotechnology industry. Read More

HARP to seek high-risk science, infrastructure to grow U.K. biopharma

LONDON – The U.K. is to move ahead with the creation of an advanced research program that will put in place large-scale infrastructures and carry out high-risk science needed to support development of entirely new industries in health care. The Health Advanced Research Programme (HARP) will form a central pillar of a new industrial strategy, designed to help life sciences prosper post-Brexit. Read More

‘Sprucing’ up the place: $20M series A takes lead asset into phase II in CAH

Spruce Biosciences Inc. landed a $20 million series A last year but kept the financing under wraps, waiting for its only asset, SPR-001, to achieve its first clinical milestone. With a phase II study now testing the small molecule in adults with congenital adrenal hyperplasia (CAH), the San Francisco-based company opted to shed a bit of light on its strategy. Read More

Human interest story: CRL wants Acelrx data on dose, text to prevent device flubs

Acelrx Pharmaceuticals Inc. CEO Vincent Angotti said he was “hesitant to put a timeline on this until we get further clarification from the FDA” regarding what’s required to satisfy the agency’s issues raised in a complete response letter (CRL) related to its NDA for 30-mg sublingual tablet Dsuvia (sufentanil), an opioid therapy that’s intended to reduce moderate to severe acute pain as well as dosing errors that can happen with intravenous administration. Read More

NIH, biopharmas launch PACT to improve cancer biomarker testing

The NIH and 11 big biopharma companies have agreed to contribute $215 million to fund a new five-year effort to facilitate systematic and uniform clinical testing of biomarkers to understanding mechanisms of response and resistance to cancer immunotherapy. Read More

Regulatory front

The FDA released a draft guidance on developing antiviral drugs for prophylaxis and treatment of respiratory syncytial virus (RSV) infection. The draft discusses nonclinical development, early phases of clinical development and phase III trial designs. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe